Ultra-rare and common genetic variant analysis converge to implicate negative selection and neuronal processes in the aetiology of schizophrenia.
Wonuola A AkingbuwaAnke R HammerschlagMeike BartelsMichel G NivardChristel M MiddeldorpPublished in: Molecular psychiatry (2022)
Both common and rare genetic variants (minor allele frequency >1% and <0.1% respectively) have been implicated in the aetiology of schizophrenia. In this study, we integrate single-cell gene expression data with publicly available Genome-Wide Association Study (GWAS) and exome sequenced data in order to investigate in parallel, the enrichment of common and (ultra-)rare variants related to schizophrenia in several functionally relevant gene-sets. Four types of gene-sets were constructed 1) protein-truncating variant (PTV)-intolerant (PI) genes 2) genes expressed in brain cell types and neurons ascertained from mouse and human brain tissue 3) genes defined by synaptic function and location and 4) intersection genes, i.e., PI genes that are expressed in the human and mouse brain cell gene-sets. We show that common as well as ultra-rare schizophrenia-associated variants are overrepresented in PI genes, in excitatory neurons from the prefrontal cortex and hippocampus, medium spiny neurons, and genes enriched for synaptic processes. We also observed stronger enrichment in the intersection genes. Our findings suggest that across the allele frequency spectrum, genes and genetic variants likely to be under stringent selection, and those expressed in particular brain cell types, are involved in the same biological pathways influencing the risk for schizophrenia.
Keyphrases
- genome wide
- genome wide identification
- single cell
- copy number
- bipolar disorder
- dna methylation
- bioinformatics analysis
- gene expression
- genome wide analysis
- prefrontal cortex
- spinal cord
- transcription factor
- stem cells
- genome wide association study
- rna seq
- mesenchymal stem cells
- electronic health record
- high throughput
- small molecule
- wastewater treatment
- cerebral ischemia
- binding protein